A study from Northwestern Medicine identifies a gut microbiome compound, propionate, that may mitigate Alzheimer's disease symptoms. The research, which involved antibiotics altering gut microbiota in Alzheimer's model mice, revealed that propionate regulates brain inflammation and amyloid plaque accumulation. Mice given propionate exhibited lower inflammation levels and fewer toxic plaques, indicating a potential cause-and-effect relationship. The findings suggest that the gut-brain connection could provide new avenues for Alzheimer's treatment as the number of dementia patients rises significantly with an aging population.
There are differences in Alzheimer's patients and their gut microbiota, and that's been verified by many groups now. Prior research has shown that when you make changes in the gut microbiota of Alzheimer model mice, you in turn have effects on the pathology of the hallmarks of Alzheimer's - amyloid plaques and tau accumulation.
Propionate plays a crucial role in regulating brain inflammation and amyloid plaque buildup - two key features of the devastating neurodegenerative condition.
Collection
[
|
...
]